bluuebunny/crossref_metadata_2025 huggingface dataset:
Psychogenic Nonepileptic Seizures Associated with an Eating Disorder and PTSD Are Responsive to Cognitive Processing Therapy
Authors: Gearhart Marina G. , Brewerton Timothy D.
Published: November 2023

Objective. Eating disorders (EDs) are often associated with prior histories of trauma, subsequent PTSD and related psychiatric comorbidities. There is a paucity of information about their relationship to somatic symptom disorders, specifically psychogenic nonepileptic seizures (PNES), a type of functional neurological symptom disorder or conversion disorder. Methods. We report a case of a 39-year-old bisexual female with bulimia nervosa (BN), PTSD, recurrent major depressive disorder (MDD), cannabis use disorder, and PNES who responded to integrated trauma-focused treatment during residential ED treatment using cognitive processing therapy (CPT). Symptoms of ED, PTSD, major depression, and state-trait anxiety were measured using validated assessment instruments. Results. During the course of CPT treatment, the patient’s total scores on the PTSD Symptom Checklist for DSM-5 (PCL-5) went from 59 to 26, which is below the diagnostic threshold for PTSD. In addition, she demonstrated improvements in the Eating Disorder Examination Questionnaire (EDE-Q) Global Severity score, the Eating Disorder Inventory (EDI-2) total score, the Patient Health Questionnaire (PHQ-9) total score, the Spielberger State and Trait Anxiety Inventory scores, and the Eating Disorder Quality of Life (EDQOL) total score. Furthermore, her PNES also abated, and she remained seizure free for ∼1 year following discharge with the exception of one short seizure, per report of the patient. Conclusion. The use of CPT as part of an integrated trauma-informed treatment approach during residential ED treatment was successful in a woman with PNES, BN, PTSD, MDD, and cannabis use disorder.
Ready-to-Eat Foods: A Potential Vehicle for the Spread of Coagulase-Positive Staphylococci and Antimicrobial-Resistant Staphylococcus aureus in Buea Municipality, South West Cameroon
Authors: Esemu Seraphine Nkie , Njoh Sally Tabe , Ndip Lucy Mande , Keneh Nene Kaah , Kfusi Jerome Achah , Njukeng Achiangia Patrick
Published: November 2023

The consumption of ready-to-eat (RTE) foods contaminated with coagulase-positive staphylococci (CoPS) and especially Staphylococcus aureus puts consumers at a potential risk of food-borne disease or colonization and subsequent infection. This cross-sectional study determined the levels of CoPS and the presence of S. aureus in RTE foods sold in Buea municipality. A total of 420 RTE food samples, comprising 70 each of cake, bread, fruit salad, meat hot-pot, suya, and boiled rice were randomly purchased from February to August 2020. The CoPS counts were determined by culturing on Baird-Parker agar, and S. aureus was identified by amplification of the nuc gene using the polymerase chain reaction. All S. aureus isolates were screened for the presence of classical staphylococcal enterotoxin genes. To determine antimicrobial resistance profiles, each isolate was tested against 11 antimicrobials. Oxacillin-resistant S. aureus strains were analyzed for the presence of the mecA gene. Overall, 161 (38.3%) samples had detectable levels of CoPS ranging from 2.0 to 5.81 log10 CFU/g. Based on CoPS levels, 37 (8.81%) of the 420 RTE food samples–only fruit salad and meat hot-pot, had unsatisfactory microbiological quality. A total of 72 S. aureus isolates, comprising 52.78% from fruit salad, 16.67% from meat hot-pot, 12.5% from boiled rice, 9.72% from suya, 5.56% from bread, and 4.17% from cake, were recovered. None of the S. aureus isolates possessed any of the classical enterotoxin genes. All the isolates were susceptible to vancomycin and ofloxacin, while 68 (94.44%) and 66 (91.67%) were susceptible to oxacillin and ciprofloxacin, respectively. Resistance to penicillin (93.06%) was highest, followed by amoxicillin (91.67%) and erythromycin (79.17%). Four isolates were identified as methicillin-resistant S. aureus, all of which carried the mecA gene. A total of 24 antibiotypes were identified. Our findings showed that RTE foods sold in the Buea municipality are likely vehicles for the transmission of CoPS and antimicrobial-resistant S. aureus.
Real-Time Remote Patient Monitoring and Alarming System for Noncommunicable Lifestyle Diseases
Authors: Ko Htet Yamin Ko , Tripathi Nitin Kumar , Mozumder Chitrini , Muengtaweepongsa Sombat , Pal Indrajit
Published: November 2023

Telemedicine and remote patient monitoring (RPM) systems have been gaining interest and received adaptation in healthcare sectors since the COVID-19 pandemic due to their efficiency and capability to deliver timely healthcare services while containing COVID-19 transmission. These systems were developed using the latest technology in wireless sensors, medical devices, cloud computing, mobile computing, telecommunications, and machine learning technologies. In this article, a real-time remote patient monitoring system is proposed with an accessible, compact, accurate, and low-cost design. The implemented system is designed to an end-to-end communication interface between medical practitioners and patients. The objective of this study is to provide remote healthcare services to patients who need ongoing care or those who have been discharged from the hospital without affecting their daily routines. The developed monitoring system was then evaluated on 1177 records from MIMIC-III clinical dataset (aged between 19 and 99 years). The performance analysis of the proposed system achieved 88.7% accuracy in generating alerts with logistic regression classification algorithm. This result reflects positively on the quality and robustness of the proposed study. Since the processing time of the proposed system is less than 2 minutes, it can be stated that the system has a high computational speed and is convenient to use in real-time monitoring. Furthermore, the proposed system will fulfil to cover the lower doctor-to-patient ratio by monitoring patients from remote locations and aged people who reside in their residences.
Supplementary Table 5 from Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC)
Authors: Wang Shuo , Onyeaghala Guillaume C. , Pankratz Nathan , Nelson Heather H. , Thyagarajan Bharat , Tang Weihong , Norby Faye L. , Ugoji Chinenye , Joshu Corinne E. , Gomez Christian R. , Couper David J. , Coresh Josef , Platz Elizabeth A. , Prizment Anna E.
Published: November 2023

Supplemental table 5 shows the associations between pre-selected SNPs and risk of CRC with and without adjustment for sMICA and sMICB levels.
Supplementary Table 4 from Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC)
Authors: Wang Shuo , Onyeaghala Guillaume C. , Pankratz Nathan , Nelson Heather H. , Thyagarajan Bharat , Tang Weihong , Norby Faye L. , Ugoji Chinenye , Joshu Corinne E. , Gomez Christian R. , Couper David J. , Coresh Josef , Platz Elizabeth A. , Prizment Anna E.
Published: November 2023

Supplemental Table 4 shows the associations of Visit 2 sMICA and sMICB levels (in quartiles) with CRC risk.
Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
Authors: Sun Maxine , Cyr Marie-Christyne , Sandoval Johanna , Lemieux Perreault Louis-Philippe , Busque Lambert , Tardif Jean-Claude , Dubé Marie-Pierre
Published: November 2023

Supplementary Table 3: Sensitivity analyses by Cox regression considering additional covariates
Supplementary Table 2 from Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC)
Authors: Wang Shuo , Onyeaghala Guillaume C. , Pankratz Nathan , Nelson Heather H. , Thyagarajan Bharat , Tang Weihong , Norby Faye L. , Ugoji Chinenye , Joshu Corinne E. , Gomez Christian R. , Couper David J. , Coresh Josef , Platz Elizabeth A. , Prizment Anna E.
Published: November 2023

Supplemental Table 2 shows the associations between pre-selected SNPs and Visit 2 sMICA and sMICB levels (continuous variables) stratified by sex, race, or diabetes status.
Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
Authors: Sun Maxine , Cyr Marie-Christyne , Sandoval Johanna , Lemieux Perreault Louis-Philippe , Busque Lambert , Tardif Jean-Claude , Dubé Marie-Pierre
Published: November 2023

Supplementary Table 13: Cox regression analyses for the effect of mosaic chromosomal alterations on the risk of death of coronary artery disease causes by cancer type
Supplemental Table 7 from Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors
Authors: Gonzalez Nicole , Rao Nina , Dean Michael , Lee Donghyuk , Hurson Amber N. , Baris Dalsu , Schwenn Molly , Johnson Alison , Prokunina-Olsson Ludmila , Friesen Melissa C. , Zhu Bin , Rothman Nathaniel , Silverman Debra T. , Koutros Stella
Published: November 2023

Cosine similarities for all signatures
Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
Authors: Sun Maxine , Cyr Marie-Christyne , Sandoval Johanna , Lemieux Perreault Louis-Philippe , Busque Lambert , Tardif Jean-Claude , Dubé Marie-Pierre
Published: November 2023

Supplementary Table 10: The effect of expanded mosaic chromosomal alterations on death of cardiovascular disease causes, coronary artery disease causes, from cancer, and any cause of death
Supplemental Table 6 from Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors
Authors: Gonzalez Nicole , Rao Nina , Dean Michael , Lee Donghyuk , Hurson Amber N. , Baris Dalsu , Schwenn Molly , Johnson Alison , Prokunina-Olsson Ludmila , Friesen Melissa C. , Zhu Bin , Rothman Nathaniel , Silverman Debra T. , Koutros Stella
Published: November 2023

Ever diesel and nitro-PAH signatures adjusted for smoking
Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
Authors: Sun Maxine , Cyr Marie-Christyne , Sandoval Johanna , Lemieux Perreault Louis-Philippe , Busque Lambert , Tardif Jean-Claude , Dubé Marie-Pierre
Published: November 2023

Supplementary Figure 2: Visual mapping of mosaic chromosomal alterations
Supplemental Table 1 from Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors
Authors: Gonzalez Nicole , Rao Nina , Dean Michael , Lee Donghyuk , Hurson Amber N. , Baris Dalsu , Schwenn Molly , Johnson Alison , Prokunina-Olsson Ludmila , Friesen Melissa C. , Zhu Bin , Rothman Nathaniel , Silverman Debra T. , Koutros Stella
Published: November 2023

Genes on panel
Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies
Authors: Hathaway Cassandra A. , Conejo-Garcia Jose R. , Fridley Brooke L. , Rosner Bernard , Saeed-Vafa Daryoush , Moran Segura Carlos , Nguyen Jonathan V. , Hecht Jonathan L. , Sasamoto Naoko , Terry Kathryn L. , Tworoger Shelley S. , Townsend Mary K.
Published: November 2023

Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics
Supplemental Table 1 from Five-year Survival Trends for Young Adult Cancers Diagnosed from 2002 to 2014 in Taiwan and the United States
Authors: Tsai Yu-Han , Teng Yu-Tung , Kuan Tai-Chuan , Liu Jason J.
Published: November 2023

APC values for five-year age-standardized relative survival trends with more than one joinpoint segment
Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies
Authors: Hathaway Cassandra A. , Conejo-Garcia Jose R. , Fridley Brooke L. , Rosner Bernard , Saeed-Vafa Daryoush , Moran Segura Carlos , Nguyen Jonathan V. , Hecht Jonathan L. , Sasamoto Naoko , Terry Kathryn L. , Tworoger Shelley S. , Townsend Mary K.
Published: November 2023

Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII
Supplementary Table S6 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Authors: Salvatore Maxwell , Hu Miriam M. , Beesley Lauren J. , Mondul Alison M. , Pearce Celeste Leigh , Friese Christopher R. , Fritsche Lars G. , Mukherjee Bhramar
Published: November 2023

Logistic regression odds ratios (95% CI) for COVID-19 outcomes by hematologic malignancy type.
Supplementary Table S4 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Authors: Salvatore Maxwell , Hu Miriam M. , Beesley Lauren J. , Mondul Alison M. , Pearce Celeste Leigh , Friese Christopher R. , Fritsche Lars G. , Mukherjee Bhramar
Published: November 2023

Logistic regression odds ratios (95% CI) for COVID-19 outcomes by chemotherapy treatment (without hematologic malignancy patients).
Supplementary Table S1 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Authors: Salvatore Maxwell , Hu Miriam M. , Beesley Lauren J. , Mondul Alison M. , Pearce Celeste Leigh , Friese Christopher R. , Fritsche Lars G. , Mukherjee Bhramar
Published: November 2023

Phecodes used to identify individuals with cancer, along with their phenotype description and the number of individuals in the tested positive cohort with the corresponding phecode.
Table S3 from Trend in Cervical Cancer Incidence and Mortality Rates in China, 2006–2030: A Bayesian Age-Period-Cohort Modeling Study
Authors: Yuan Meiwen , Zhao Xuelian , Wang Honghao , Hu Shangying , Zhao Fanghui
Published: November 2023

Table S3 shows proportion of incidence cases by age group between 2006 to 2016.
Supplementary Figure S8 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Authors: Salvatore Maxwell , Hu Miriam M. , Beesley Lauren J. , Mondul Alison M. , Pearce Celeste Leigh , Friese Christopher R. , Fritsche Lars G. , Mukherjee Bhramar
Published: November 2023

Severe COVID-19 among recent cancer (within three years of positive COVID-19 test; n = 6,143) and non-cancer patients (n = 41,545) who tested positive and have non-missing covariates. The results were from the model logit P(YSevereCOVID = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
Table S2 from Trend in Cervical Cancer Incidence and Mortality Rates in China, 2006–2030: A Bayesian Age-Period-Cohort Modeling Study
Authors: Yuan Meiwen , Zhao Xuelian , Wang Honghao , Hu Shangying , Zhao Fanghui
Published: November 2023

Table S2 shows trends for age-specific cervical cancer incidence and mortality rates by region in China between 2006 to 2016.
Supplementary Figure S5 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Authors: Salvatore Maxwell , Hu Miriam M. , Beesley Lauren J. , Mondul Alison M. , Pearce Celeste Leigh , Friese Christopher R. , Fritsche Lars G. , Mukherjee Bhramar
Published: November 2023

Severe COVID-19 among cancer (n = 12,995) and non-cancer patients (n = 34,693) who tested positive and had non-missing covariates. The results were from the model logit P(YSevereCOVID = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
Supplementary Figure S1 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Authors: Salvatore Maxwell , Hu Miriam M. , Beesley Lauren J. , Mondul Alison M. , Pearce Celeste Leigh , Friese Christopher R. , Fritsche Lars G. , Mukherjee Bhramar
Published: November 2023

Flowchart describing derivation of COVID-19 tested analytic cohort from raw COVID-19 tested data.
Supplementary Table 3 from Low-Carbohydrate Diet Score and the Risk of Colorectal Cancer: Findings from the Singapore Chinese Health Study
Authors: Yu Yi-Chuan , Paragomi Pedram , Jin Aizhen , Wang Renwei , Schoen Robert E. , Koh Woon-Puay , Yuan Jian-Min , Luu Hung N.
Published: November 2023

Supplementary Table S3 describes results from models without BMI variable adjustment (overall)
Table S5 from Exploring the Complex Relationship between Gut Microbiota and Risk of Colorectal Neoplasia Using Bidirectional Mendelian Randomization Analysis
Authors: Li Wanxin , Zhou Xuan , Yuan Shuai , Wang Lijuan , Yu Lili , Sun Jing , Chen Jie , Xiao Qian , Wan Zhongxiao , Zheng Ju-Sheng , Zhang Cai-Xia , Larsson Susanna C. , Farrington Susan M. , Law Philip , Houlston Richard S. , Tomlinson Ian , Ding Ke-Feng , Dunlop Malcolm G. , Theodoratou Evropi , Li Xue
Published: November 2023

Table S5 shows the SNPs for adenoma and polyps.
Data from Trend in Cervical Cancer Incidence and Mortality Rates in China, 2006–2030: A Bayesian Age-Period-Cohort Modeling Study
Authors: Yuan Meiwen , Zhao Xuelian , Wang Honghao , Hu Shangying , Zhao Fanghui
Published: November 2023

AbstractBackground:
There are no studies extrapolating the incidence and mortality of cervical cancer in China by comparing incidence and deaths pattern between geographic and age groups.
Methods:
We applied age-period-cohort models to assess region-level trends in incidence and mortality from 2006 to 2016, with piecewise linear regression in a Bayesian framework to predict these trends to 2030.
Results:
Between 2006 and 2016, age-standardized incidence rates (ASIR) for females aged 15 to 84 years increased by 3.7% (95% confidence interval, 3.1%–4.3%) annually from 11.01 to 16.41 per 100,000 females in China. In the 25 to 39 age groups, the incidence rates decreased in urban regions and inversely increased in rural regions. The age-standardized mortality rates (ASMR) increased from 3.18 to 4.83, with annual increases of about 3.6% (1.5%–5.8%). From 2017 to 2030, the ASIR is expected to increase from 17.13 (15.91–18.46) to 23.22 (20.02–27.01) by 2.5% per year (P < 0.05). Meanwhile, the average age at diagnosis is predicted to grow from 53.1 to 60.5 years. In the 15 to 54 age groups, the incidence rates decreased in urban regions but increased in rural regions. The ASMR is expected to increase consistently from 4.82 (4.38–5.31) to 9.13 (7.35–11.39) by 5.0% per year (P < 0.05).
Conclusions:
Cervical cancer incidence and mortality rates are projected to increase in China. In addition, the urban–rural incidence gap is estimated to widen further among young women.
Impact:
Cervical cancer prevention should consider the trend and diversity in incidence patterns between urban and rural regions.
Data from Survival of Middle Eastern and North African Individuals Diagnosed with Colorectal Cancer: A Population-Based Study in California
Authors: Zaki Timothy A. , Ziogas Argyrios , Chang Jenny , Murphy Caitlin C. , Anton-Culver Hoda
Published: November 2023

AbstractBackground:
Literature on colorectal cancer outcomes in individuals of Middle Eastern and North African (MENA) descent is limited. To address this gap, we estimated five-year colorectal cancer–specific survival by race and ethnicity, including MENA individuals, in a diverse, population-based sample in California.
Methods:
We identified adults (ages 18–79 years) diagnosed with a first or only colorectal cancer in 2004 to 2017 using the California Cancer Registry (CCR), including non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, Hispanic, and MENA individuals. For each racial/ethnic group, we calculated five-year colorectal cancer–specific survival and used Cox proportional hazards regression models to examine the association of race/ethnicity and survival, adjusting for clinical and socio demographic factors.
Results:
Of 110,192 persons diagnosed with colorectal cancer, five-year colorectal cancer–specific survival was lowest in Black (61.0%) and highest in MENA (73.2%) individuals. Asian (72.2%) individuals had higher survival than White (70.0%) and Hispanic (68.2%) individuals. In adjusted analysis, MENA [adjusted HR (aHR), 0.82; 95% confidence interval (CI), 0.76–0.89], Asian (aHR, 0.86; 95% CI, 0.83–0.90), and Hispanic (aHR, 0.94; 95% CI, 0.91–0.97) race/ethnicity were associated with higher, and Black (aHR, 1.13; 95% CI, 1.09–1.18) race/ethnicity was associated with lower survival compared with non-Hispanic White race/ethnicity.
Conclusions:
To our knowledge, this is the first study to report colorectal cancer survival in MENA individuals in the United States. We observed higher survival of MENA individuals compared with other racial/ethnic groups, adjusting for sociodemographic and clinical factors.
Impact:
Future studies are needed to identify factors contributing to cancer outcomes in this unique population.
Data from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
Authors: Howlader Nadia , Sharon Elad , Bhattacharya Manami , Ehrlich Lori A. , Richardson Nicholas C. , Gormley Nicole J. , de Claro R. Angelo , Wood Amy E. , Mariotto Angela B. , Cronin Kathleen A.
Published: November 2023

AbstractIntroduction:
Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL–bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality trends compared with acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).
Methods:
Because mortality trends reflect combined effects of leukemia incidence and survival, we also evaluated the contribution of incidence and survival trends to mortality trends by subtypes. We used data from 13 U.S. (SEER) registries (1992–2017) among U.S. adults. We utilized histology codes to identify cases of CML, ALL, and CLL and death certificate data to calculate mortality. We used Joinpoint to characterize incidence (1992–2017) and mortality (1992–2018) trends by subtype and diagnosis year.
Results:
For CML, mortality rates started declining in 1998 at an average rate of 12% annually. Imatinib was approved by the FDA for treating CML and ALL in 2001, leading to clear benefits for patients with CML. Five-year CML survival increased dramatically over time, especially between 1996 to 2011, 2.3% per year on average. ALL incidence increased 1.5% annually from 1992 to 2017. ALL mortality decreased 0.6% annually during 1992 to 2012 and then stopped declining. CLL incidence fluctuated during 1992 to 2017 while mortality decreased 1.1% annually during 1992 to 2011 and at a faster rate of 3.6% per year from 2011. Five-year survival increased 0.7% per year on average during 1992 to 2016.
Conclusions:
Survival benefit from TKIs and other novel therapies for treating leukemia subtypes has been demonstrated in clinical trials.
Impact:
Our study highlights the impact of molecularly targeted therapies at the population level.
Supplementary Table 1 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Table 1
Supplementary Figure 8 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 8. Fimepinostat treatment of NEPC tumors is associated with tumor growth inhibition, apoptosis, and diminished ASCL1 expression.
Supplementary Figure 6 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 6. Fimepinostat treatment of prostate adenocarcinoma tissue slices causes growth inhibition and inhibition of AR and Myc.
Supplementary Figure 4 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 4. Enforced expression of AR-FL, Myc, or activated AKT1 does not rescue the growth inhibitory effects of fimepinostat therapy.
Supplementary Figure 17 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 17. Pathway analysis of hallmark (A) and KEGG (B) genes from C4-2B and NCI-H660 cells treated with vehicle, fimepinostat, ipatasertib, romidepsin, or a combination of ipatasertib + romidepsin.
Supplementary Figure 13 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 13. Dual AKT-PI3K and HDAC inhibition can have additive and synergistic effects in C4-2B and NCI-H660 cells.
Supplementary Figure 11 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 11. Analysis of the cell division index in viable tumor cells post-romidepsin and fimepinostat in vivo.
Supplementary Figure 1 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Supplementary Figure 1. ARPC and NEPC metastases within the same patient.
FIGURE 5 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Fimepinostat significantly inhibits tumor growth in NEPC PDX models relative to the HDAC inhibitor romidepsin alone. NEPC PDX models (LuCaP 145.1 and LuCaP 208.1) were treated with 1.5 mg/kg romidepsin [(A) LuCaP 145.1, n = 11; (B) LuCaP 208.1 n = 11] or 75 mg/kg fimepinostat [(C) LuCaP 145.1, n = 9; (D) LuCaP 208.1 n = 11] or vehicle control (LuCaP 145.1, n = 8; LuCaP 208.1, n = 11) for up to 3.5 weeks. Blue = vehicle vs. red = romidepsin or fimepinostat. P values = *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
FIGURE 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Transcriptional changes associated with fimepinostat treatment are largely conserved between CRPC and NEPC. A, Venn diagrams showing overlapping upregulated and downregulated genes in the 22Rv1 and LNCaP95 cell lines after treatment with 1 µmol/L fimepinostat relative to treatment with 0.1% DMSO for 24 hours. B, Plots showing commonly enriched (top, yellow bars) and de-enriched (bottom, blue bars) MSigDB hallmark gene sets from GSEA of overlapping genes in A. C, Gene expression heat map of 22Rv1 and LNCaP95 cells treated with DMSO or increasing doses of fimepinostat for 24 hours. Select genes including Myc, AR, AR targets, NE markers, and EMT markers are shown. D, Venn diagrams showing overlapping upregulated and downregulated genes in the NCI-H660 and MSKCC EF1 cell lines after treatment with 1 µmol/L fimepinostat relative to treatment with 0.1% DMSO for 24 hours. E, Plots showing commonly enriched (top, yellow bars) and de-enriched (bottom, blue bars) MSigDB hallmark gene sets from GSEA of overlapping genes in D. F, Gene expression heat map of NCI-H660 or MSKCC EF1 cells treated with DMSO or increasing doses of fimepinostat for 24 hours. Select genes including Myc paralogs and NE transcription factors are shown. G, Plot showing the overall changes in gene expression of transcription factors after treatment with 1 µmol/L fimepinostat relative to treatment with 0.1% DMSO for 24 hours. Select highly enriched and de-enriched transcription factors are labeled.
FIGURE 2 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Authors: Zhang Ailin , Lau Nathan A. , Wong Alicia , Brown Lisha G. , Coleman Ilsa M. , De Sarkar Navonil , Li Dapei , DeLucia Diana C. , Labrecque Mark P. , Nguyen Holly M. , Conner Jennifer L. , Dumpit Ruth F. , True Lawrence D. , Lin Daniel W. , Corey Eva , Alumkal Joshi J. , Nelson Peter S. , Morrissey Colm , Lee John K.
Published: November 2023

Fimepinostat inhibits AR and Myc expression at the transcriptional level and suppresses full-length and variant expression. Plots showing RQ of AR (A) and Myc RNA (B) species based on qRT-PCR analysis of 22Rv1 and LNCaP95 cells treated with 1 µmol/L fimepinostat over a time course. Results are normalized to the 0 hour condition. Immunoblot analyses of cycloheximide chase experiments to evaluate AR (C) and Myc protein (D) stability after treatment of the 22Rv1 and LNCaP95 cell lines with 0.1% DMSO or 1 µmol/L fimepinostat. E, Immunoblot analyses for the 22Rv1 and LNCaP95 cell lines stably transduced with conditional Tet-on shRNA expression lentiviruses (targeting GFP as a control or different AR isoforms) and treated with doxycycline and/or 1 µmol/L fimepinostat for 24 hours. F, Immunoblot analyses of the CWR-R1 and CWR-R1-D567 cell lines after 24 hours of treatment with DMSO control or increasing doses of fimepinostat to determine the effects on expression of AR-FL and AR-Vs including ARv567es.
Quality of Life After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting
Authors: Dimagli Arnaldo , Spadaccio Cristiano , Myers Annie , Demetres Michelle , Rademaker‐Havinga Tessa , Stone Gregg W. , Spertus John A. , Redfors Bjorn , Fremes Stephen , Gaudino Mario , Masterson Creber Ruth
Published: November 2023

Background

Differences in quality of life (QoL) after coronary artery bypass grafting (CABG) compared with percutaneous coronary intervention (PCI) are not well characterized. We aimed to compare the short‐ and long‐term effects of CABG versus PCI on QoL.

Methods and Results

We performed a systematic review and meta‐analysis of randomized controlled trials comparing CABG versus PCI using the Seattle Angina Questionnaire (SAQ)‐Angina Frequency, SAQ‐QoL, SAQ‐Physical Limitations, EuroQoL‐5D, and Short‐Form Questionnaire. We calculated mean changes within each group from baseline to 1, 6, 12, and 36 to 60 months (latest follow‐up) and the weighted mean differences between groups using inverse‐variance methods. A total of 10 760 patients were enrolled in 5 trials. From baseline to 12 months and 36 to 60 months, the mean change in SAQ‐Angina Frequency was >22 points (95% CI, 21.0–25.6) after both PCI and CABG. The mean difference in SAQ‐Angina Frequency was similar between procedures at 1 month and at 36 to 60 months but favored CABG at 12 months (1.97 [95% CI, 0.68–3.26]). SAQ‐QoL favored PCI at 1 month (−2.92 [95% CI, −4.66 to −1.18]) and CABG at 6 (2.50 [95% CI, 1.02–3.97]), 12 (3.30 [95% CI, 1.78–4.82]), and 36 to 60 months (3.17 [95% CI, 0.54 5.80). SAQ‐Physical Limitations (−12.61 [95% CI, −16.16 to −9.06]) and EuroQoL‐5D (−0.07 [95% CI, −0.08 to −0.07) favored PCI at 1 month. Short‐Form Questionnaire‐Physical Component favored CABG at 12 months (1.18 [95% CI, 0.46–1.90]).

Conclusions

Both PCI and CABG improved long‐term disease‐specific and generic QoL.
Thrombus Aspirates From Patients With Acute Ischemic Stroke Are Infiltrated by Viridans Streptococci
Authors: Patrakka Olli , Tuomisto Sari , Pienimäki Juha‐Pekka , Ollikainen Jyrki , Oksala Niku , Lampinen Vili , Ojanen Markus J. T. , Huhtala Heini , Hytönen Vesa P. , Lehtimäki Terho , Martiskainen Mika , Karhunen Pekka J.
Published: November 2023

Background

Acute ischemic stroke may be due to embolism from ruptured atherosclerotic carotid arteries. DNA of oral bacteria, mainly the viridans streptococci group, has been detected in thrombus aspirates of patients with ischemic stroke as well as in carotid endarterectomy samples. Because viridans streptococci are known to possess thrombogenic properties, we studied whether their presence in thrombus aspirates and in carotid artery specimens can be confirmed using bacterial immunohistochemistry.

Methods and Results

Thrombus aspirates from 61 patients with ischemic stroke (70.5% men; mean age, 66.8 years) treated with mechanical thrombectomy, as well as carotid endarterectomy samples from 20 symptomatic patients (65.0% men; mean age, 66.2 years) and 48 carotid artery samples from nonstroke autopsy cases (62.5% men; mean age, 66.4 years), were immunostained with an antibody cocktail against 3 species (
Streptococcus sanguinis
,
Streptococcus mitis,
and
Streptococcus gordonii
) of viridans streptococci. Of the thrombus aspirates, 84.8% were immunopositive for viridans streptococci group bacteria, as were 80.0% of the carotid endarterectomy samples, whereas immunopositivity was observed in 31.3% of the carotid artery samples from nonstroke autopsies. Most streptococci were detected inside neutrophil granulocytes, but there were also remnants of bacterial biofilm as well as free bacterial infiltrates in some samples.

Conclusions

Oral streptococci were found in aspirated thrombi of patients with acute ischemic stroke as well as in carotid artery samples. Our results suggest that viridans streptococci group bacteria may play a role in the pathophysiology of ischemic stroke.
Within‐Physician Differences in Patient Sharing Between Primary Care Physicians and Cardiologists Who Treat White and Black Patients With Heart Disease
Authors: Matthews Luke J. , Damberg Cheryl L. , Zhang Shiyuan , Escarce Jose J. , Gibson C. Ben , Schuler Megan , Popescu Ioana
Published: November 2023

Background

Black‐White disparities in heart disease treatment may be attributable to differences in physician referral networks. We mapped physician networks for Medicare patients and examined within‐physician Black‐White differences in patient sharing between primary care physicians and cardiologists.

Methods and Results

Using Medicare fee‐for‐service files for 2016 to 2017, we identified a cohort of Black and White patients with heart disease and the primary care physicians and cardiologists treating them. To ensure the robustness of within‐physician comparisons, we restricted the sample to regional health care markets (ie, hospital referral regions) with at least 10 physicians sharing ≥3 Black and White patients. We used claims to construct 2 race‐specific physician network measures: degree (number of cardiologists with whom a primary care physician shares patients) and transitivity (network tightness). Measures were adjusted for Black‐White differences in physician panel size and calculated for all settings (hospital and office) and for office settings only. Of 306 US hospital referral regions, 226 and 145 met study criteria for all settings and office setting analyses, respectively. Black patients had more cardiology encounters overall (6.9 versus 6.6;
P
<0.001) and with unique cardiologists (3.0 versus 2.6;
P
<0.001), but fewer office encounters (31.7% versus 41.1%;
P
<0.001). Primary care physicians shared Black patients with more cardiologists than White patients (mean differential degree 23.4 for all settings and 3.6 for office analyses;
P
<0.001 for both). Black patient‐sharing networks were less tightly connected in all but office settings (mean differential transitivity −0.2 for all settings [
P
<0.001] and near 0 for office analyses [
P
=0.74]).

Conclusions

Within‐physician Black‐White differences in patient sharing exist and may contribute to disparities in cardiac care.
Noninvasive Hemodynamic Characterization of Shock and Preshock Using Echocardiography in Cardiac Intensive Care Unit Patients
Authors: Jentzer Jacob C. , Burstein Barry , Ternus Bradley , Bennett Courtney E. , Menon Venu , Oh Jae K. , Anavekar Nandan S.
Published: November 2023

Background

Shock and preshock are defined on the basis of the presence of hypotension, hypoperfusion, or both. We sought to determine the hemodynamic underpinnings of shock and preshock noninvasively using transthoracic echocardiography (TTE).

Methods and Results

We included Mayo Clinic cardiac intensive care unit patients from 2007 to 2015 with TTE within 1 day of admission. Hypotension and hypoperfusion at the time of cardiac intensive care unit admission were used to define 4 groups. TTE findings were evaluated across these groups, and in‐hospital mortality was evaluated according to TTE findings in each group. We included 5375 patients with a median age of 69.2 years (36.8% women). The median left ventricular ejection fraction was 50%. Groups based on hypotension and hypoperfusion were assigned as follows: no hypotension or hypoperfusion, 59.7%; isolated hypotension, 15.3%; isolated hypoperfusion, 16.4%; and both hypotension and hypoperfusion, 8.7%. Most TTE variables of interest varied across these groups, with worse biventricular function, lower forward flow, and higher filling pressures as the degree of hemodynamic compromise increased. In‐hospital mortality occurred in 8.2%, and inpatient deaths had more TTE parameter abnormalities. In‐hospital mortality increased with the degree of hemodynamic compromise, and a marked gradient in in‐hospital mortality was observed when the clinical classification of shock and preshock was combined with TTE findings reflecting worse biventricular function, lower forward flow, or higher filling pressures.

Conclusions

Substantial differences in cardiac function are observed between cardiac intensive care unit patients with preshock and shock using TTE, and the combination of the clinical and TTE hemodynamic assessment provides robust mortality risk stratification.
Management of Patients With Unexplained Syncope: Derivation and Validation of a Simplified 2‐Step Diagnostic Approach
Authors: Doundoulakis Ioannis , Tsiachris Dimitris , Kordalis Athanasios , Koliastasis Leonidas , Soulaidopoulos Stergios , Arsenos Petros , Xintarakou Anastasia , Bartsioka Lamprini Iro , Dilaveris Polychronis , Vlachopoulos Charalambos , Sideris Skevos , Tsioufis Konstantinos , Gatzoulis Konstantinos A.
Published: November 2023

Background

The aim of this study was to develop a structured 2‐step approach, based on noninvasive diagnostic criteria, that led to an electrophysiology study in patients with unexplained syncope.

Methods and Results

Two independent cohorts were used: the derivation cohort with 665 patients based on electronic health record data to develop our 2‐step diagnostic approach, and the validation cohort based on 160 prospectively screened patients, presenting with unexplained syncope episodes. Noninvasive electrocardiographic and imaging markers and an electrophysiology study–based invasive assessment were combined. A positive diagnostic approach according to our study's prespecified criteria resulted in a decision to proceed with a permanent pacemaker/implantable cardioverter‐defibrillator. The primary end point was the time until the event of recurrent syncope (syncope‐free survival). Number needed to treat was calculated for patients with a positive diagnostic approach. The number of patients with unexplained syncope and borderline sinus bradycardia needed to treat was 5, and the number of patients with unexplained syncope and bundle branch block needed to treat was 3 over a mean follow‐up of ≈4 years. After the structured 2‐step approach, the primary outcome occurred in 14 of 82 (17.1%) with a pacemaker/implantable cardioverter‐defibrillator and 19 of 57 (33%) with a negative approach, with a mean follow‐up of ≈2.5 years (29.29±12.58 months,
P
=0.03).

Conclusions

The low number needed to treat in the derivation cohort and the low percentage of syncope recurrence in the validation cohort supports the proposed 2‐step electrophysiology‐inclusive algorithm as a potentially low‐cost, 1‐day, structured tool for these patients.
Contribution of the
APOE
Genotype to Cognitive Impairment in Individuals With
NOTCH3
Cysteine‐Altering Variants
Authors: Cheng Yu‐Wen , Liao Yi‐Chu , Chen Chih‐Hao , Chung Chih‐Ping , Fann Cathy S. J. , Chang Chien‐Ching , Lee Yi‐Chung , Tang Sung‐Chun
Published: November 2023

Background

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most prevalent monogenic cerebral small‐vessel disease. Phenotype variability in CADASIL suggests the possible role of genetic modifiers. We aimed to investigate the contributions of the
APOE
genotype and Neurogenic locus notch homolog protein 3 (
NOTCH3
) variant position to cognitive impairment associated with CADASIL.

Methods and Results

Patients with the cysteine‐altering
NOTCH3
variant were enrolled in a cross‐sectional study, including the Mini‐Mental State Examination (MMSE), brain magnetic resonance imaging, and
APOE
genotyping. Cognitive impairment was defined as an MMSE score <24. The associations between the MMSE score and genetic factors were assessed using linear regression models. Bayesian adjustment for confounding was used to identify clinical confounders. A total of 246 individuals were enrolled, among whom 210 (85%) harbored the p.R544C variant, 96 (39%) had cognitive impairment, and 150 (61%) had a history of stroke. The
APOE
ɛ2 allele was associated with a lower MMSE score (adjusted
B
, −4.090 [95% CI, −6.708 to −1.473];
P
=0.023), whereas the
NOTCH3
p.R544C variant was associated with a higher MMSE score (adjusted
B
, 2.854 [95% CI, 0.603–5.105];
P
=0.0132) after adjustment for age, education, and history of ischemic stroke. Mediation analysis suggests that the associations between the
APOE
ɛ2 allele and MMSE score and between the
NOTCH3
p.R544C variant and MMSE score are mediated by mesial temporal atrophy and white matter hyperintensity, respectively.

Conclusions

APOE
genotype may modify cognitive impairment in CADASIL, whereby individuals carrying the
APOE
ɛ2 allele may present a more severe cognitive impairment.
A resource for development and comparison of multimodal brain 3 T MRI harmonisation approaches
Authors: Warrington Shaun , Ntata Asante , Mougin Olivier , Campbell Jon , Torchi Andrea , Craig Martin , Alfaro-Almagro Fidel , Miller Karla L. , Morgan Paul S. , Jenkinson Mark , Sotiropoulos Stamatios N.
Published: November 2023

Despite the huge potential of magnetic resonance imaging (MRI) in mapping and exploring the brain, MRI measures can often be limited in their consistency, reproducibility, and accuracy which subsequently restricts their quantifiability. Nuisance nonbiological factors, such as hardware, software, calibration differences between scanners, and post-processing options, can contribute to, or drive trends in, neuroimaging features to an extent that interferes with biological variability. Such lack of consistency, known as lack of harmonisation, across neuroimaging datasets poses a great challenge for our capabilities in quantitative MRI. Here, we build a new resource for comprehensively mapping the extent of the problem and objectively evaluating neuroimaging harmonisation approaches. We use a travelling-heads paradigm consisting of multimodal MRI data of 10 travelling subjects, each scanned at five different sites on six different 3 T scanners from all the three major vendors and using five neuroimaging modalities, providing more comprehensive coverage than before. We also acquire multiple within-scanner repeats for a subset of subjects, setting baselines for multimodal scan-rescan variability. Having extracted hundreds of imaging-derived phenotypes, we compare three forms of variability: (i) between-scanner, (ii) within-scanner (within-subject), and (iii) biological (between-subject). We characterise the reliability of features across scanners and use our resource as a testbed to enable new investigations that until now have been relatively unexplored. Specifically, we identify optimal pipeline processing steps that minimise between-scanner variability in extracted features (implicit harmonisation). We also test the performance of post-processing harmonisation tools (explicit harmonisation) and specifically check their efficiency in reducing between-scanner variability against baseline standards provided by our data. Our explorations allow us to come up with good practice suggestions on processing steps and sets of features where results are more consistent, while our publicly released dataset (which we refer to as ON-Harmony) establishes references for future studies in this field.